TITLE:
Preliminary Guidelines for the Use of IVIg during COVID-19
AUTHORS:
David S. Younger
KEYWORDS:
SARS-CoV-2, Immune Globulin, Neurological, Nervous System, Post-Acute Sequelae, COVID-19
JOURNAL NAME:
World Journal of Neuroscience,
Vol.11 No.2,
May
31,
2021
ABSTRACT: Infection
with the severe acute respiratory syndrome novel type-2 novel coronavirus
(SARS-CoV-2) responsible for the 2019 coronavirus disease (COVID-19) shows a highly
heterogeneous clinical presentation and age affliction in children and adults,
ranging from asymptomatic or mild disease to severe involvement, with potentially fatal respiratory failure and multiple organ
dysfunction. As susceptibility to severe COVID-19 depends upon comorbid factors
including immune competence, optimizing the latter through low-dose
supplementation or high dose treatment with immune globulin therapy in those
with primary immune deficiency and post-infectious immune sequelae of
SARS-CoV-2 and existing autoimmune disorders is essential. There are no
existing guidelines hence; this paper provides a framework for considering
preliminary guidelines for the use of immune globulin therapy during COVID-19.